Table 4 Poor prognostic factors of HCC after non-curative therapy.

Variable	Case No.	Univariate analysis		Multivariate analysis
Variable	Case No.	Hazard ratio (95% CI)	p	Hazard ratio (95% CI)	p
Age > 65/≤65 years	329/275	0.758(0.623–0.922)	0.005
Sex male/female	476/128	1.459(1.136–1.874)	0.003	1.487(1.150–1.924)	0.003
HBsAg positive/negative	329/273	1.510(1.238–1.843)	<0.001
Anti-HCV positive/negative	171/432	0.804(0.645–1.000)	0.050
Albumin ≤4/>4 g/dL	520/83	1.776(1.312–2.405)	<0.001	1.773(1.293–2.432)	<0.001
Bilirubin >1.6/≤1.6 mg/dL	185/419	1.799(1.464–2.210)	<0.001	1.875(1.508–2.332)	<0.001
ALT > 40/≤40 U/L	373/231	1.227(1.001–1.505)	0.049
AST > 45/≤45 U/L	447/144	1.872(1.455–2.409)	<0.001
Platelet ≤10⁵/>10⁵/mm³	191/413	1.025(0.831–1.265)	0.818
PT INR > 1.1/≤1.1	330/274	1.206(0.990–1.468)	0.063
Ascites (yes/no)	244/360	2.851(2.334–3.482)	<0.001
AFP > 20/≤20 ng/ml	427/176	2.360(1.855–3.003)	<0.001	1.975(1.532–2.546)	<0.001
Multiple tumor (yes/no)	353/251	1.178(0.965–1.439)	0.108
Tumor size > 3/≤3 cm	503/101	3.112(2.242–4.318)	<0.001	2.615(1.855–3.688)	<0.001
Vascular invasion (yes/no)	254/350	3.076(2.510–3.771)	<0.001	2.458(1.978–3.054)	<0.001
EGV (yes/no)	337/267	1.492(1.221–1.822)	<0.001	1.254(1.013–1.553)	0.038

Abbreviations: CI: confidence interval; HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; MELD: model for end-stage liver disease; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Alk-P: alkaline phosphate; PT INR: prothrombin time international normalized ratio; AFP: alpha-fetoprotein; EGV: esophagogastric varices.

Quick links

Search